1.1Laser ablation of superficial deposits
A 193 nm excimer laser ablates thin layers of deposit-bearing anterior corneal tissue. Anterior segment optical coherence tomography maps deposit depth and guides the planned ablation depth.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A 193 nm excimer laser ablates thin layers of deposit-bearing anterior corneal tissue. Anterior segment optical coherence tomography maps deposit depth and guides the planned ablation depth.
A pars plana vitrectomy uses a small-gauge cutter and aspiration to extract the gel and entrained aggregates. An infusion maintains intraocular pressure as the cutter removes the opacified gel.
Deep anterior lamellar keratoplasty removes the deposit-bearing stroma and preserves the recipient endothelium. A donor corneal graft with its endothelium removed is sutured into the stromal bed to restore a clear optical path.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Retinal explants from a canine model of inherited retinal degeneration sit photoreceptor-side up on porous culture inserts. The test compound enters the culture medium beneath each insert, and matched explants from the same retina receive vehicle. Immunostaining quantifies intracellular deposits of the target protein in photoreceptors, and a matched viability measurement accounts for photoreceptor loss.
Rapamycin serves as the active compound in a retinal organoid culture that accumulates a misfolded photoreceptor protein. Rapamycin inhibits mechanistic target of rapamycin complex 1 and induces autophagy. A pulse-chase immunoassay tracks decay of the preexisting target protein, and paired wells with lysosomal inhibition quantify the lysosomal contribution to turnover.
Retinal organoids occupy separate wells assigned to pulsed exposure, continuous exposure, or vehicle control. The pulsed group receives the compound for 2 hours every 24 hours for 3 days, with compound-free medium between pulses. The continuous group receives the same nominal concentration for 72 hours, and separate replicate wells provide target-protein measurements at 0, 24, 48, and 72 hours.
A two-channel microfluidic culture chip holds a retinal organoid and a retinal pigment epithelium monolayer in adjacent compartments separated by a porous membrane. A syringe pump delivers compound-containing medium through the organoid compartment, and a separate pump supplies the epithelial compartment. Timed outlet samples track compound concentration, and endpoint imaging measures intracellular accumulation of the target protein.
Poly(lactic-co-glycolic acid) microspheres encapsulate the clearance-promoting compound and sit in a porous insert above a retinal organoid culture. The insert retains the microspheres while released compound diffuses into the shared medium. Serial medium samples quantify the release profile by liquid chromatography, and matched organoids exposed to unloaded microspheres provide a control for protein-turnover measurements.
Photoreceptor cultures express a misfolded target protein fused to a photoconvertible fluorescent tag. An automated microscope photoconverts the tag immediately before compound addition and reimages the same fields at fixed intervals. Software segments and tracks cells, corrects converted-channel intensity for photobleaching using reference wells, and fits a decay rate for the marked protein pool in each surviving cell.
A basic active compound is formulated as a hydrochloride salt in a sterile buffered solution for corneal delivery. The concentration, drop volume, and dosing interval determine the amount applied to the ocular surface.
A crystalline monohydrate of a systemically absorbed active compound is blended with microcrystalline cellulose and filled into hard capsules. The fill mass accounts for the lattice water so that each capsule delivers the specified mass of active compound on an anhydrous basis.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
According to the invention, the compounds may be administered hourly, daily, weekly, monthly or annually. In another embodiment, the effective amount of the compound comprises from about 0.000001 mg/kg body weight to about 100 mg/kg body weight.A · US 2012/0189615 A1 · ¶ 99
As shown in FIG. 14, an exemplary syringe 80 applicator is administering a therapeutic dose 204 into an affected area by injection. The therapeutic dose is a composition derived from thawing a frozen dose, as described herein and comprises live amniotic stem cells 30, a cryoprotectant 234 and a buffer 232.B · US 2017/0095515 A1 · ¶ 67
An empty cell means only that no passage was reproduced there.
Amyloid peptides or proteins are cytotoxic to cells.A · US 2012/0189615 A1 · ¶ 5
The invention furthermore discloses the identification of the formation of a cross-β structure as a signal for protein degradation and/or protein clearance.A · US 2012/0189615 A1 · ¶ 8
This is inconvenient and in some cases impractical, especially when a dose of an amniotic stem cell therapeutic composition is required multiple times a day.B · US 2017/0095515 A1 · ¶ 5
A frozen therapeutic dose may be provided in a form, such as a multi-pack form, to enable a person to administer a dose to a treatment location without the need of traveling to a doctor's office or clinic.B · US 2017/0095515 A1 · ¶ 7
patent.fyi, US 2026/0355203 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355203/, SHA-256 6b1531a76440124358160bb53b2448d46b9ef5cbe44ec15aa1dc5979312670cd